Impact News +++ Is It Worth Investing in Trip.com (TCOM) Based on Wall Street′s Bullish Views? (Zacks) +++ TRIP.COM ADR Aktie +3,06%

10X GENOMICS Aktie

>10X GENOMICS Aktienkurs

9.42 EUR +1.1% (Tradegate)

Ask: 9.402 EUR / 2130 Stück

Bid: 9.34 EUR / 2150 Stück

Tagesumsatz: 601 Stück

Realtime Kurs von 8 bis 22 Uhr!

10X GENOMICS Aktie über LYNX handeln

Intraday

1 Jahr

>10X GENOMICS Performance

1 Woche: +2,2%

1 Monat: +20,1%

3 Monate: -3,5%

6 Monate: -35,0%

1 Jahr: -49,8%

laufendes Jahr: -33,4%

>10X GENOMICS Aktie

Name:

10X GENOMICS DL -,00001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US88025U1097 / A2PPQJ

Symbol/ Ticker:

1KJ (Frankfurt) / TXG (NASDAQ)

Kürzel:

FRA:1KJ, ETR:1KJ, 1KJ:GR, NASDAQ:TXG

Index:

Webseite:

https://www.10xgenomics.c..

Marktkapitalisierung:

1010 Mio. EUR

Umsatz:

548.16 Mio. EUR

EBITDA:

-128.89 Mio. EUR

Gewinn je Aktie:

-1.018 EUR

Schulden:

70.26 Mio. EUR

Liquide Mittel:

374.62 Mio. EUR

Umsatz-/ Gewinnwachstum:

9.8% / -

KGV/ KGV lG:

- / -

KUV/ KBV/ PEG:

1.74 / 1.56 / -

Gewinnm./ Eigenkapitalr.:

-25.14% / -22.03%

Dividende je Aktie:

Dividendenrendite/ -schätzung:

- / -

Insiderhandel:

3 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 173.222 USD.

Suchwörter:

10X GENOMICS, 10XGENOMICS

Letzte Datenerhebung:

24.06.25

>10X GENOMICS Eigentümer

Aktien: 111.09 Mio. St.

f.h. Aktien: 109.01 Mio. St.

Insider Eigner: 1.93%

Instit. Eigner: 102.11%

Leerverk. Aktien: 14.8%

>10X GENOMICS Peer Group

ACCURAY

APPLIED THERAPEUTICS

ARTIVION

COMPASS PATHWAYS

DENALI THERAPEUTICS

ORTHOFIX

STAAR SURGICAL

SUPERNUS

WEST PHARMACEUTICAL

XOMA ROYALTY

>10X GENOMICS Chart & Kurs - NASDAQ

>10X GENOMICS News

29.05.25 - 17:30	Wall Street Analysts Think 10x Genomics (TXG) Could Surge 43.12%: Read This Before Placing a Bet (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 43.1% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

28.05.25 - 00:01	Insiderhandel: Vorstand verkauft Aktien von 10X Genomics im Wert von 62120 USD (Insiderkauf)
	Hindson, Benjamin J. - Vorstand - Tag der Transaktion: 2025-05-22...

28.05.25 - 00:01	Insiderhandel: Chief Financial Officer verkauft Aktien von 10X Genomics im Wert von 33562 USD (Insiderkauf)
	Taich, Adam - Vorstand - Tag der Transaktion: 2025-05-22...

28.05.25 - 00:01	Insiderhandel: Chief Executive Officer verkauft Aktien von 10X Genomics im Wert von 77540 USD (Insiderkauf)
	Saxonov, Serge - Vorstand - Tag der Transaktion: 2025-05-22...

23.05.25 - 14:12	Why 10x Genomics Stock Was Sliding This Week (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

21.05.25 - 19:45	10x Genomics (TXG) Upgraded to Buy: Here′s What You Should Know (Zacks)
	10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

14.05.25 - 22:09	10x Genomics Announces Patent Litigation Settlement Agreement with Bruker (PR Newswire)
	PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and......

14.05.25 - 13:54	Bruker and 10x Genomics reach global settlement of patent litigation (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.05.25 - 17:30	Wall Street Analysts Believe 10x Genomics (TXG) Could Rally 55.85%: Here′s is How to Trade (Zacks)
	The average of price targets set by Wall Street analysts indicates a potential upside of 55.9% in 10x Genomics (TXG). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

09.05.25 - 09:39	10x Genomics CEO Calls NIH The Foundational Jewel Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance (Benzinga)
	10x Genomics Inc. criticized U.S. government budget cuts for academic research, withdrew full-year guidance, and shifted to quarterly forecasts. read more...

09.05.25 - 02:30	Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics (Zacks)
	Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers....

08.05.25 - 22:06	10x Genomics Reports First Quarter 2025 Financial Results (PR Newswire)
	PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8......

30.04.25 - 22:06	10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference (PR Newswire)
	PLEASANTON, Calif., April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13,......

14.04.25 - 22:09	10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025 (PR Newswire)
	PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a......

05.03.25 - 02:01	Insiderhandel: Chief Executive Officer verkauft Aktien von 10X Genomics im Wert von 84393 USD (Insiderkauf)
	Saxonov, Serge - Vorstand - Tag der Transaktion: 2025-02-28...

03.03.25 - 22:48	10x Genomics gets injunction against Parse Biosciences′ ATAC Products (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.25 - 22:09	10x Genomics Secures Injunction Against Parse Biosciences′ Planned ATAC Products (PR Newswire)
	10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered......

27.02.25 - 03:01	Insiderhandel: Vorstand verkauft Aktien von 10X Genomics im Wert von 50603 USD (Insiderkauf)
	Hindson, Benjamin J. - Vorstand - Tag der Transaktion: 2025-02-24...

27.02.25 - 03:01	Insiderhandel: Chief Executive Officer verkauft Aktien von 10X Genomics im Wert von 56346 USD (Insiderkauf)
	Saxonov, Serge - Vorstand - Tag der Transaktion: 2025-02-24...

26.02.25 - 01:01	Insiderhandel: Aufsichtsrat kauft Aktien von 10X Genomics im Wert von 445572 USD (Insiderkauf)
	Mateo, Alan - Aufsichtsrat - Tag der Transaktion: 2025-02-21...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram